Acceso abierto

Effects of naringin and valproate interaction on liver steatosis and dyslipidaemia parameters in male C57BL6 mice

David Jutrić

David Jutrić

  • University of Zagreb Faculty of ScienceZagreb, Croatia
  • Clinical Hospital DubravaZagreb, Croatia
Buscar este autor en
Sciendo|Google Scholar
Jutrić, David
, 
Domagoj Đikić

Domagoj Đikić

University of Zagreb Faculty of ScienceZagreb, Croatia
Perfil de Orcid
Buscar este autor en
Sciendo|Google Scholar
Đikić, Domagoj
, 
Almoš Boroš

Almoš Boroš

University of Zagreb Faculty of ScienceZagreb, Croatia
Buscar este autor en
Sciendo|Google Scholar
Boroš, Almoš
, 
Dyna Odeh

Dyna Odeh

University of Zagreb Faculty of ScienceZagreb, Croatia
Buscar este autor en
Sciendo|Google Scholar
Odeh, Dyna
, 
Sandra Domjanić Drozdek

Sandra Domjanić Drozdek

University of Applied Health SciencesZagreb, Croatia
Buscar este autor en
Sciendo|Google Scholar
Drozdek, Sandra Domjanić
, 
Romana Gračan

Romana Gračan

University of Zagreb Faculty of ScienceZagreb, Croatia
Buscar este autor en
Sciendo|Google Scholar
Gračan, Romana
, 
Petar Dragičević

Petar Dragičević

University of Zagreb School of MedicineZagreb, Croatia
Buscar este autor en
Sciendo|Google Scholar
Dragičević, Petar
, 
Irena Crnić

Irena Crnić

University of Zagreb Faculty of Food Technology and BiotechnologyZagreb, Croatia
Buscar este autor en
Sciendo|Google Scholar
Crnić, Irena
 y 
Irena Landeka Jurčević

Irena Landeka Jurčević

University of Zagreb Faculty of Food Technology and BiotechnologyZagreb, Croatia
Buscar este autor en
Sciendo|Google Scholar
Jurčević, Irena Landeka
  
07 abr 2022
Effects of naringin and valproate interaction on liver steatosis and dyslipidaemia parameters in male C57BL6 mice's Cover Image
Acerca de este artículo
Artículo anterior
Artículo siguiente
Cite
Descargar portada
Categoría del artículo: Original article
Publicado en línea: 07 abr 2022
Páginas: 71 - 82
Recibido: 01 oct 2021
Aceptado: 01 feb 2022
DOI: https://doi.org/10.2478/aiht-2022-73-3608
Palabras clave
© 2022 David Jutrić, Domagoj Đikić, Almoš Boroš, Dyna Odeh, Sandra Domjanić Drozdek, Romana Gračan, Petar Dragičević, Irena Crnić, Irena Landeka Jurčević, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

Figure 1

Serum lipids and lipoproteins in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. The numbers above bars represent statistically significant differences (p<0.05) between specific groups
Serum lipids and lipoproteins in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. The numbers above bars represent statistically significant differences (p<0.05) between specific groups

Figure 2

Lipid steatosis stained with Oil Red in the liver of control mice (A) and mice treated with daily doses of 150 mg/kg bw valproate (B), 25 mg/ kg bw naringin (C), and their combination (D) for 10 days
Lipid steatosis stained with Oil Red in the liver of control mice (A) and mice treated with daily doses of 150 mg/kg bw valproate (B), 25 mg/ kg bw naringin (C), and their combination (D) for 10 days

Figure 3

Liver lipid metabolism regulators in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. The numbers above bars represent statistically significant differences (p<0.05) between specific groups
Liver lipid metabolism regulators in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. The numbers above bars represent statistically significant differences (p<0.05) between specific groups

Figure 4

Liver tissue oxidative stress parameters in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. The numbers above bars represent statistically significant differences (p<0.05) between specific groups. MDA – malondialdehyde
Liver tissue oxidative stress parameters in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. The numbers above bars represent statistically significant differences (p<0.05) between specific groups. MDA – malondialdehyde

Figure 5

Liver tissue antioxidants in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. The numbers above bars represent statistically significant differences (p<0.05) between specific groups. SOD – total superoxide dismutase activity; CAT – catalase activity; GSH – reduced glutathione
Liver tissue antioxidants in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. The numbers above bars represent statistically significant differences (p<0.05) between specific groups. SOD – total superoxide dismutase activity; CAT – catalase activity; GSH – reduced glutathione

Figure 6

Transcription factor Nrf2 in the liver of control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. No significant differences were observed between the groups
Transcription factor Nrf2 in the liver of control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days. No significant differences were observed between the groups

Serum biochemistry parameters in control mice and mice treated with daily doses of 150 mg/kg bw valproate, 25 mg/kg bw naringin, and their combination for 10 days

Parameter Control Valproate Naringin Valproate+Naringin
Glucose (mmol/L)
Mean ± SD 5.9±0.9 12.7±1.4a 14.0±4.2a,b 17.8±1.5b
Median 5.8 12.6 13.4 16.3
Range 5.0–7.2 11.5–14.3 9.8–19.3 9.8–19.9
Amylase activity (U/L)
Mean ± SD 365.3±110.6 555.0±520.4a 371.8±23.8 455.8±102.4b
Median 331.0 355.0 373.5 459.0
Range 273.0–526.0 184.0–1326.0 342.0–398.0 356.0–549.0
Lactate dehydrogenase (LDH) activity (U/L)
Mean ± SD 264.8±29.2 316.4±40.3a 382.0±97.8a 498.5±324.2a
Median 257.0 331.0 392.0 531.5
Range 240.0–305.0 250.0–348.0 263.0–518.0 122.0–809.0
Creatinine (mg/L)
Mean ± SD 22.8±3.3 31.3±7.8a 27.5±10.5 42.8±3.6b
Median 22.5 29.0 25.0 43.0
Range 19.0–27.0 25.0–42.0 18.0–42.0 24.0–56.0
Bound urea nitrogen (BUN) (mmol/L)
Mean ± SD 6.0±1.3 10.2±7.6a 6.9±1.1 10.0±3.4a
Median 5.7 8.5 7.0 8.5
Range 4.8–7.7 3.0–21.0 5.4–8.0 7.9–15.0
Bilirubin (μmol/L)
Mean ± SD 5.3±0.2 5.6±0.4 5.1±0.2 5.1±0.2
Median 5.3 5.8 5.0 5.1
Range 5.0–5.5 5.1–5.9 5.0–5.4 5.0–5.4
Alkaline phosphatase (ALP) activity (U/L)
Mean ± SD 46.3±6.3 44.5±3.1 32.0±14.1 42.0±2.2
Median 47.3 45.5 38.5 41.5
Range 40.0–55.0 40.0–47.0 11.0–40.0 40.0–45.0
Total proteins (mg/L)
Mean ± SD 37.3±5.0 34.5±10.2 40.5±5.9 38.1±0.9
Median 37.5 37.5 40.0 38.0
Range 32.0–42.0 20.0–43.0 37.0–49.0 37.0–39.0
Albumin (mg/L)
Mean ± SD 27.0±2.4 34.3±6.5 36.0±5.0 31.0±0.8
Median 26.5 36.0 36.0 30.0
Range 25.0–30.0 25.0–40.0 30.0–42.0 29.0–33.0
Idiomas:
Inglés, Croatian, Slovenian
Calendario de la edición:
4 veces al año
Temas de la revista:
Medicina, Ciencias médicas básicas, Ciencias médicas básicas, otros
RSS Feed de revista